BrightInsight and CSL Behring expand partnership with enterprise agreement for patient apps

Csl blog

Today at #HLTH in Las Vegas, we announced an expanded partnership with CSL Behring to build, launch and maintain digital solutions for CSL Behring’s late-stage and marketed rare disease medicines. BrightInsight will also serve as legal manufacturer of record (LMR) for the solutions. Our partnership with CSL Behring began in May 2020 to develop the Hizentra® app for adult patients taking Hizentra.

According to Brian Johnson, Senior Director, Customer Engagement at CSL Behring, they selected BrightInsight because we had the only regulated solution with a robust Quality Management System and comprehensive privacy and security certifications. CSL Behring wanted a partner to provide the underlying digital technology that would allow them to scale their digital solutions across countries and disease states.

The enterprise agreement includes plans for additional apps and geographic expansion. 

CSL Behring is an outstanding partner that values digital’s power to provide insights that can improve outcomes, increase medication adherence and enhance the patient experience. The Hizentra app we helped CSL Behring build and launch in just six months is a great example of the incredible impact digital can have.

The Hizentra® app supports patients with two rare diseases, Primary Immune Deficiency (PI) or Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), who are transitioning from in-clinic to at-home self-administered infusions of Hizentra. The app helps patients track infusions, set reminders and share their infusion journal with an HCP. The Hizentra app has been downloaded by thousands of patients and has an Apple App Store rating of 4.6 stars.

The app is also an engine for real-world data, providing powerful insights on patient experience and behavior which enable opportunities to improve care. There are insights CSL was able to uncover that would not be identified via typical market research.

Our latest CSL Behring case study shows that the app has been adopted by 20% of the people taking this medication in the U.S., with a retention rate of 89% — compared to the industry average of 45%. And the app is helping patients administer Hizentra:  the company has captured over 800,000 electronic patient reported outcomes (ePROs) and over 160,000 at-home self-administrations of the drug.

We are thrilled to expand our partnership and introduce new digital health products across CSL Behring’s portfolio of rare disease medicines, leveraging our platform and out-of-the-box solutions to drive speed to market, enable global expansion and deliver value for patients.

Back to Blog